Our 3rd an­nu­al UK bio­phar­ma event tops this week — on Zoom — with José Basel­ga, top biotech CEOs and a look at the glob­al fi­nan­cial scene

The first few years of Pas­cal So­ri­ot’s reign as CEO of As­traZeneca were tough to watch, at times. Set­backs were more com­mon than break­throughs, and its in­abil­i­ty to fin­ish its new head­quar­ters build­ing in Cam­bridge, UK, seemed em­blem­at­ic of its in­ner con­fu­sion. True, So­ri­ot had in­her­it­ed the worst pipeline in Big Phar­ma, but in­vestors fret­ted for some time when the com­pa­ny would get back on track.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN